Cancers that
keep coming back…

Meet doctors
who never give up

Clinicians

Omico provides access to new trials and treatments for your patients with rare, advanced, difficult-to-treat or early-onset cancers.

Cancer Meet Its Match

Opportunities for the clinical community

video_icon

Why collaborate with Omico?

1

Get help finding and triaging trial options for your patients.

2

Access comprehensive genomic profiling at no cost to your patient to identify clinical trials and treatments specific to your patient’s cancer sub-type.

3

Get faster, curated and qualified recommendations.

4

Get support setting up clinical trials that may have previously been impossible due to low patient numbers.

How our genomic screening works

Appropriate patients with later-stage cancer that is not responding to current treatment or at high-risk for cancer (due to hereditary conditions):

  • You complete an online referral form
  • The patient signs a consent form
  • Cancer tissue undergoes molecular profiling
  • Molecular Tumour Board matches results to an existing therapy or clinical trial of a new drug
  • Process takes 8 to 10 weeks
More about Omico About PrOSPeCT

How Omico streamlines research

Omico is proactively screening thousands of patients with comprehensive genomic profiling to streamline clinical trial enrolment and save costs.

Standard biomarker screening

Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.

$500
per test
$50,000
per patient identified
200
specific biomarkers per $10M

Comprehensive genomic profiling

CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers for multiple trials all at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.

Annual reports About us
$2,500
per test
$25,000
per patient identified
400
specific biomarkers per $10M

Our Progress

7,000 Patients screened
3,991 Patients with a treatment recommendation
608    Clinical trial referrals (C1/C2)
800 Referring clinicians

Referring patients to our programs

Cancer Screening Program

Our Cancer Screening Program (CaSP) brings comprehensive genomic profiling to patients with advanced and incurable cancer and helping identify potential treatments or clinical trials.

Learn more Refer a Patient

Match a patient’s molecular changes to targeted therapy

Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy or clinical trial.

Learn more

Identify the genetic basis of a patient’s cancer risk

We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.

Learn more Refer a patient
RisC and SMOC diagram

Improve the surveillance of patients at risk of multi-organ cancer

Our Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer.

Learn more Refer a patient
RisC and SMOC diagram

Learn more about MoST clinical trials

There are 23 MoST substudies:

  • 16 core studies run by Omico
  • 4 companion studies run by Omico in collaboration with partner organisations
  • 3 company studies sponsored by industry partners

FAQs

  • What will MoST do?

    If your patient is eligible for the screening program we will:

    • Consent your patient into the screening study
    • Arrange to access tumour tissue held by a pathology centre
    • Arrange for collection of a blood sample
    • Analyse the tissue (molecular profiling)
    • Following review by our molecular tumour board (MTB), provide you with a report containing the tumour’s molecular profile and therapeutic recommendations including clinical trials

  • Is my patient eligible for the MoST program?

    If you answer “yes” to the following statements your patient may qualify for the pancreatic cancer and leukaemia/lymphoma cohorts.

    Your patient:

    • is aged 18 years or older, with pathologically confirmed advanced and/or metastatic cancer of any histologic type, including haematological cancers, or an earlier diagnosis of a poor prognosis cancer
    • has tissue available for molecular screening
    • has no more than one standard treatment available
    • is self-caring in all activities of daily living, and out of bed more than half of each day (ECOG performance status 0, 1 or 2)
    • is not pregnant, lactating or planning to become pregnant

    If you answer “yes” to the following statements your patient may qualify for the lung cancer cohort.

    Your patient:

    • is aged 18 years or older, with newly diagnosed pathologically confirmed metastatic non-squamous non-small cell lung cancer (NSCLC)
    • has tissue available for molecular screening
    • has an ECOG performance status of 0 or 1
    • has not had any previous treatment for metastatic non-squamous NSCLC

     

    More information about ASPiRATION and the ASPiRATION referral form

  • How do I refer patients?

    To get your patient onto the molecular screening stage of the program you will need to:

    • Contact us or complete the MoST referral form (see the link below); for ASPiRATION follow the link above
    • Supply a histopathology report for your patient and any relevant clinical information
    • Receive the results of the molecular screening test and discuss the results with your patient
    • If appropriate and available, refer your patient to a MoST clinical trial or follow up on treatment options highlighted in the screening report
    • Continue to provide us with follow up information about your patient.

    MoST program referral form

Our network

Omico is a nationwide network of research and treatment centres that facilitate, support and promote genomic cancer medicine.

Information, resources and support networks

Rare Cancer Australia

Rare Cancer Australia (RCA) provides support and advocacy for patients wishing to participate in Omico programs. If you or your family need advice or help, a place to learn or simply someone to listen, RCA can help.

Visit the RCA website

Canteen

If you are aged from 12 to 25 and your world has been turned upside down by cancer, Canteen provides support as well as someone to talk to.

Visit the Canteen website

Australian Rare Cancer Portal

The Australian Rare Cancer (ARC) Portal is an online referral service that aims to improve outcomes and access to research for Australians diagnosed with rare cancer.

Working together with your cancer specialist, the ARC Portal offers expert clinical advice, particularly for Australians who live far away from major metropolitan centres where cancer centres may not be available.

Visit the ARC Portal

Work with us to help patients access genomic profiling and innovative new therapies

Get in touch